Genmab names Ahmadi CMO, head of experimental medicines; plus moves at Wugen and Aevitas 

Genmab A/S (CSE:GMAB; NASDAQ:GMAB) promoted Tahamtan Ahmadi from SVP, head of oncology to EVP and CMO, head of experimental medicines, a newly created position. Before joining Genmab in 2017, Ahmadi was VP, head of experimental medicine and early development oncology at the Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ). 

Cell therapy developer Wugen Inc. hired Jan Davidson as CMO. Davidson was senior director for clinical research at MacroGenics Inc. (NASDAQ:MGNX). Wugen also said Monday that it partnered with Washington University in St. Louis to develop the biotech’s Memory Natural Killer Cell program. Wugen was founded based on technology licensed from the university. ...